| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-351
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-346
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3233
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-314
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-353 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-65846
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1131
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-65616
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-65583
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-65586
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16 |
| filingDate |
2012-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2015-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2015500204-A |
| titleOfInvention |
Functionally modified oligonucleotides and subunits thereof |
| abstract |
Functionally modified oligonucleotide analogs comprising modified intersubunit linkages and / or modified 3 'and / or 5' end groups are provided. The disclosed compounds are useful in the treatment of diseases, where inhibition of protein expression or modulation of aberrant mRNA splice products results in beneficial therapeutic effects. In one embodiment, a compound comprising a backbone comprising a sequence of morpholino ring structures connected by an intersubunit linkage connecting the 3 ′ end of a morpholino ring structure to the 5 ′ end of an adjacent morpholino ring structure, each Described herein are compounds in which the morpholino ring structure is attached to a base-pairing moiety and the compound can bind to a target nucleic acid in a sequence specific manner. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021095875-A1 |
| priorityDate |
2011-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |